256 related articles for article (PubMed ID: 22566605)
1. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Blum W; Schwind S; Tarighat SS; Geyer S; Eisfeld AK; Whitman S; Walker A; Klisovic R; Byrd JC; Santhanam R; Wang H; Curfman JP; Devine SM; Jacob S; Garr C; Kefauver C; Perrotti D; Chan KK; Bloomfield CD; Caligiuri MA; Grever MR; Garzon R; Marcucci G
Blood; 2012 Jun; 119(25):6025-31. PubMed ID: 22566605
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Walker AR; Klisovic RB; Garzon R; Schaaf LJ; Humphries K; Devine SM; Byrd JC; Grever MR; Marcucci G; Blum W
Leuk Lymphoma; 2014 Jun; 55(6):1304-8. PubMed ID: 23952243
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Blum W; Klisovic RB; Hackanson B; Liu Z; Liu S; Devine H; Vukosavljevic T; Huynh L; Lozanski G; Kefauver C; Plass C; Devine SM; Heerema NA; Murgo A; Chan KK; Grever MR; Byrd JC; Marcucci G
J Clin Oncol; 2007 Sep; 25(25):3884-91. PubMed ID: 17679729
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
6. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Blum W; Garzon R; Klisovic RB; Schwind S; Walker A; Geyer S; Liu S; Havelange V; Becker H; Schaaf L; Mickle J; Devine H; Kefauver C; Devine SM; Chan KK; Heerema NA; Bloomfield CD; Grever MR; Byrd JC; Villalona-Calero M; Croce CM; Marcucci G
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7473-8. PubMed ID: 20368434
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
[TBL] [Abstract][Full Text] [Related]
8. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
9. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Attar EC; De Angelo DJ; Supko JG; D'Amato F; Zahrieh D; Sirulnik A; Wadleigh M; Ballen KK; McAfee S; Miller KB; Levine J; Galinsky I; Trehu EG; Schenkein D; Neuberg D; Stone RM; Amrein PC
Clin Cancer Res; 2008 Mar; 14(5):1446-54. PubMed ID: 18316568
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
[TBL] [Abstract][Full Text] [Related]
13. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
How J; Minden MD; Brian L; Chen EX; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Webster S; Degelder T; Haines P; Stayner LA; McGill S; Wang L; Piekarz R; Wong T; Siu LL; Espinoza-Delgado I; Holleran JL; Egorin MJ; Yee KW
Leuk Lymphoma; 2015; 56(10):2793-802. PubMed ID: 25682963
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
16. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
[TBL] [Abstract][Full Text] [Related]
17. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Howard DS; Liesveld J; Phillips GL; Hayslip J; Weiss H; Jordan CT; Guzman ML
Leuk Res; 2013 Nov; 37(11):1502-8. PubMed ID: 24075534
[TBL] [Abstract][Full Text] [Related]
18. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
Tawfik B; Sliesoraitis S; Lyerly S; Klepin HD; Lawrence J; Isom S; Ellis LR; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee T
Ann Hematol; 2014 Jan; 93(1):47-55. PubMed ID: 24149914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
